Eli Lilly Acquires Three Vaccine Developers, Expanding Infectious Disease Portfolio

Eli Lilly announced on May 26, 2026 that it would acquire three vaccine developers—Curevo, LimmaTech Biologics, and Vaccine Company—for up to nearly $4 billion combined. The deals mark a significant expansion into infectious disease vaccines, funded by cash from Eli Lilly's booming GLP-1 business. The three companies are developing shots against pathogens that cause long-term health issues.

Eli Lilly vaccine acquisitions

• ▪The three vaccine developers being acquired by Eli Lilly are Curevo, LimmaTech Biologics, and Vaccine Company.
• ▪Eli Lilly announced on May 26, 2026 that Eli Lilly would buy three early- and mid-stage vaccine developers.
• ▪The three vaccine developer acquisitions by Eli Lilly could cost up to nearly $4 billion together.
• ▪The three vaccine developers being acquired by Eli Lilly are working on shots against pathogens that can cause long-term health issues.

GLP-1 revenue fueling deals

• ▪In recent months, Eli Lilly picked up companies working on cancer, autoimmune diseases, and sleep disorders, all for under $10 billion each.
• ▪Eli Lilly is rich with cash from Eli Lilly's booming GLP-1 business.

1 source